Rx Drugs
Filling the Rx Gap: Cost Solutions at the Point-of-Sale
Prescription abandonment—cited as one of the major cost-related issues in healthcare—has prompted numerous efforts to raise the profile of pharmacists in driving improvements in patient utilization. With a marked decline in engagement elsewhere—physician prescribers are seeing fewer sales reps and DTC spending is ebbing – more solutions providers are seeking to fill the gap, with new tools to help support pharmacists in providing effective cost solutions to patients directly at a medication’s point-of-sale ...Read more
Legal
Lanham Act: Peer Review on Trial
Scientific opinion has special protection under the First Amendment, but does that give pharma a free pass to BYOD – build your own dataset – publish a peer-reviewed article based on the data, and then promote it for competitive advantage? ...Read more
Regulatory
FDA's Breakthrough New Designation Process: A Patient Perspective
According to Teresa Barnes, Vice President of Patient Outreach & Program Support for the Coalition for Pulmonary Fibrosis, whether a drug is allocated to the FDA’s fast-track, breakthrough, or accelerated approval pathways, the patient voice needs to be included in the conversation. In the first of a new online series on the “Patient Voice,” she speaks with PharmExec to outline some ways to make sure patients obtain this seat at the table—the earlier, she says, the better ...Read more
SciVigilance – Pharmacovigilance in a box
Effective safety and risk management is a result of a multi-tiered effort that ensures the safety of a product and mitigates the risks for pharmaceutical companies. While pharmacovigilance depends extensively on human sources for information input and processing of data, the growing volume of data and evolving regulations necessitates robust technology enabled process execution to manage the myriad of risks. Read More
Social Media
Is Pinterest the Risk-Free Social Channel for Pharma?
Pinterest was recently desrcibed as the “safest place” for medical marketers to start with social media. All too aware that there are many Pharma marketers out there still a little shy of social, Peter Houston investigates if that's true ...Read more
|
